Jubilant Ingrevia (JUBLINGREA) Q2 25/26 earnings summary

Executive summary

• Achieved highest quarterly revenue and sales volume in the last 10 quarters, with 7% year-on-year growth and all business segments contributing.

• Specialty chemicals segment led growth with double-digit revenue increase and over 25% EBITDA margins, while nutrition business maintained steady volume growth despite pricing pressure.

• Chemical intermediates posted highest quarterly sales in six quarters, driven by acetic anhydride and ethyl acetate.

• EBITDA grew 8% year-on-year for the quarter and 18% for the half-year; PAT increased 18% for the quarter and 34% for the half-year.

• Unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2025 were approved by the Board on 27 October 2025.

Financial highlights

• Q2 FY26 consolidated revenue was ₹112,073 lakhs, up from ₹102,900 lakhs in Q2 FY25; H1 revenue was ₹215,868 lakhs.

• Q2 EBITDA at ₹146 crore, up 8% year-on-year; H1 EBITDA at ₹300 crore, up 18% year-on-year.

• Q2 PAT at ₹70 crore, up 18% year-on-year; H1 PAT up 34% year-on-year.

• Q2 CapEx was ₹59 crore, YTD CapEx at ₹109 crore, mainly for CDMO and multipurpose plants.

• Basic EPS (consolidated) for Q2 FY26 was ₹4.40, up from ₹3.73 in Q2 FY25.

Outlook and guidance

• Expect continued growth in H2 FY26, led by specialty chemicals, nutrition, and partial recovery in acetyls.

• Major CDMO order to commence in early 2026, with new multipurpose plant in Gujarat to be completed by late 2026.

• Guidance for INR 2,000 crore EBITDA remains unchanged, with ramp-up of new molecules expected to reach peak revenue in 2-3 years.

• Ongoing expansion of CDMO and Fine Chemicals portfolio, with 10+ new molecules added and more in advanced stages.